Hair Loss & Scalp Health

Finasteride / Minoxidil / Biotin / Vitamin D3 / Vitamin K2

A finasteride-and-minoxidil combination with selected micronutrients for hair-loss programs.

Evidence brief in review

lennoxHAIRProduct image pending

Common goals: Potential support for male-pattern hair loss using two ingredient pathways with human evidence.
Best program fit: May fit a structured androgenetic-alopecia offering with baseline photography, contraindication screening, and long-term follow-up.
Format: Compounded combination · exact dosage form to be confirmed

Partner education guide

Where this may fit in an offering.

Potential support for male-pattern hair loss using two ingredient pathways with human evidence. One formula may simplify administration when the route and strengths are appropriate. May support a longitudinal hair and scalp program rather than a one-time transaction.

Educational business-planning summary. Potential benefits vary, are not guaranteed, and require individual-specific clinical review.

01 / Common goals

What people may want to understand.

Primary goals

Potential benefits and goals

Potential support for male-pattern hair loss using two ingredient pathways with human evidence.
One formula may simplify administration when the route and strengths are appropriate.
Structured photography can make progress easier to evaluate.

Program value

How it may support a program

May support a longitudinal hair and scalp program rather than a one-time transaction.
Creates a reason to review diagnosis, nutrition, adherence, and reproductive considerations together.

Finasteride and topical minoxidil have ingredient-level evidence. The exact compounded format and added micronutrients have not been validated as one product.

02 / Program fit

Program and operational considerations.

01Administration format: Catalog format: Compounded combination · exact dosage form to be confirmed. The prescribing clinician and dispensing pharmacy confirm the exact preparation, concentration, handling, and administration technique.
02Typical frequency: The screenshot does not establish a schedule. Frequency must come from the exact prescription and route-specific product instructions.
03Expected duration: Hair-loss treatment is usually assessed over months and often requires continued use to maintain benefit. The exact combination has no product-matched duration study.
04Practical considerations: May support a longitudinal hair and scalp program rather than a one-time transaction.

03 / Suitability considerations

Who may be considered.

Who may be considered

A carefully screened adult whose goals align with the potential benefits above and who understands that individual response varies.
An individual willing to complete clinician-directed baseline review, monitoring, and an outcome-based follow-up plan.

Qualification notes

May support a longitudinal hair and scalp program rather than a one-time transaction.
Strongest fit occurs when the exact formulation, route, source, contraindications, and measurable goals can be clearly documented.

04 / Safety & suitability

What must be screened before treatment.

Common or temporary

Sexual adverse effects can include reduced libido, erectile or ejaculation changes, and reduced semen volume; breast tenderness or enlargement may occur.
Minoxidil effects depend on route. Topical use may cause scalp irritation, itching, unwanted facial hair, or temporary shedding; systemic exposure can cause dizziness, swelling, or a faster heartbeat.

Serious or important

Finasteride or dutasteride can affect pregnancy through exposure to the active drug and can change prostate-specific antigen interpretation. Reproductive plans and handling precautions require review.
Chest pain, fainting, rapid heartbeat, sudden swelling, serious mood change, allergic reaction, or a painful scalp reaction warrants prompt assessment.

Avoid or use only with specialist input

Pregnancy or potential pregnancy where exposure to finasteride or dutasteride could occur, hypersensitivity to a formula ingredient, or an unverified compounded product.
Sudden, patchy, scarring, inflamed, infected, or unexplained hair loss until an appropriate diagnosis is established.

Screening checklist

Confirm the hair-loss pattern and duration, scalp findings, family history, current medicines and supplements, blood-pressure and heart history, reproductive plans, sexual symptoms, mood history, and relevant laboratory evaluation.
Verify the exact dosage form, route, ingredient strengths, dispensing pharmacy, storage, and how progress will be photographed or measured.

When to refer

Refer for dermatology or medical assessment when hair loss is sudden, patchy, scarring, associated with inflammation or systemic symptoms, occurs in a child, or remains diagnostically unclear.
Prompt assessment is appropriate for chest pain, syncope, marked edema, a persistent rapid heartbeat, severe scalp reaction, pregnancy exposure, or significant sexual or mood symptoms.

Safety information is not exhaustive. Prescribing, screening, dosing, monitoring, and emergency guidance must come from an appropriately licensed clinician and the exact product information.

What the research says · reviewed August 2026

Research and source context.

Finasteride and topical minoxidil have established ingredient-level evidence; the exact compounded route and added micronutrients remain separate questions.

01 / Human research

The clearest clinical signal

Finasteride 1 mg is labeled for male pattern hair loss, topical minoxidil is labeled for defined scalp patterns, and a small trial studied a topical finasteride-minoxidil combination.

02 / Real-world reports

What people describe

People may want reduced shedding, greater density, or a simpler routine. Continued use, sexual adverse effects, scalp tolerability, and realistic photographic tracking should be discussed.

Public personal accounts are unverified and cannot show how common an outcome is.

03 / Cautions

What deserves attention

Pregnancy exposure, sexual and mood symptoms, prostate-marker interpretation, topical irritation, systemic minoxidil effects, and unknown compounded strengths require review.

Does the research match this exact product?

Partly. Ingredient and limited topical-combination evidence does not validate every compounded route, strength, or nutrient add-on.

Research and regulatory context

Finasteride labeling and minoxidil Drug Facts support ingredient-level use, and a small randomized pilot studied a topical finasteride-minoxidil combination. That evidence does not establish an unspecified compounded route, strengths, or added micronutrients.

Complete evidence briefClinical summary, safety notes, reported timing, regulatory context, and linked sources in one document.

Evidence brief in reviewReviewed sources are listed above

Evidence and regulatory status can change. Confirm the current label, formulation, route, dose, pharmacy source, jurisdiction, and intended use before offering treatment.

Education before offering.

Treatment information is for education only. It is not medical advice. A licensed clinician will review your health and decide whether a treatment is appropriate for you. Eligibility and availability may vary.

Back to all treatments